| Routes of administration | Oral[1] |
|---|---|
| Class | Sirtuin-6 (SIRT6) activator[1] |
| Cas number | 2135638-06-9 |
| Pubchem | 131964504 |
| Chemspiderid | 129910029 |
| Synonyms | SP624 |
| Iupac name | (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione |
| C | 19 |
| H | 17 |
| Cl | 1 |
| N | 2 |
| O | 6 |
| Smiles | C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC |
| Stdinchi | 1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1 |
| Stdinchikey | MIHSWFYCAJWPIS-YLVJLNSGSA-N |
Forvisirvat (INN, USAN; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.[1][2][3][4][5] It is taken by mouth.[1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.[1][2][4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.[1][2][5]
See also
References
- ^ "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.
- ^ "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.
- ^ Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults". Clinical Pharmacology in Drug Development. 14 (1): 18–25. doi:10.1002/cpdd.1488. ISSN 2160-763X. PMC 11701958. PMID 39587867
- ^ Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC 10935124. PMID 38486982
- ^ "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.